BIIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biogen Inc (BIIB) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is facing declining financial performance, insider selling, and technical indicators that do not suggest a clear upward trend. While there are positive catalysts such as acquisitions and product approvals, the overall sentiment and financial outlook remain mixed. Holding off on investing until more positive momentum is evident would be prudent.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 42.851, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 175.862, with resistance at 181.053 and support at 170.67. Overall, the technical indicators suggest a lack of strong upward momentum.
Approval of high-dose Spinraza, enhancing competitive positioning.
Acquisition of Apellis Pharmaceuticals, bringing in Syfovre and Empaveli to fill revenue gaps and strengthen the immunology portfolio.
Piper Sandler's upgrade to Overweight with a price target of $214, reflecting optimism about the company's strategic moves.
Insider selling has increased significantly by 864.10% over the last month.
Financial performance has been weak, with revenue, net income, and EPS all showing significant YoY declines in Q4
Analysts anticipate a sales decline in 2026 despite new product launches.
In Q4 2025, Biogen reported a revenue decline of -7.14% YoY to $2.28 billion. Net income dropped to -$48.9 million, down -118.34% YoY, and EPS fell to -$0.33, down -118.03% YoY. Gross margin slightly decreased to 72.46%. Despite some growth in specific product lines, the overall financial performance is weak.
Analyst sentiment is mixed. Piper Sandler upgraded the stock to Overweight with a price target of $214, citing optimism about the Apellis acquisition. However, other analysts, such as Truist and Citi, lowered their price targets, reflecting concerns about financial impacts from the acquisition and broader market conditions. Price targets range from $150 to $275, with a median around $200.
